ライフサイエンスコーパス: renal transplantation

1 -stage CKD (defined as long-term dialysis or renal transplantation).

2 acute kidney injury requiring dialysis; and renal transplantation).

3 ve a significant impact in diagnostics after renal transplantation.

4 ns of memory CD4 T cells in a mouse model of renal transplantation.

5 nts are the fastest-growing group in need of renal transplantation.

6 ney function, and this effect is reversed by renal transplantation.

7 the recent periods of increasing success in renal transplantation.

8 policy implications for maximizing value in renal transplantation.

9 specificity for the diagnosis of TCMVR after renal transplantation.

10 not be an absolute contraindication against renal transplantation.

11 e transplantation waiting list who underwent renal transplantation.

12 rogressed to ESRD and subsequently underwent renal transplantation.

13 most common cause of early graft loss after renal transplantation.

14 second primary cancers are infrequent after renal transplantation.

15 rs limiting long-term outcome in cardiac and renal transplantation.

16 e risk factors for primary CMV disease after renal transplantation.

17 properties of HDL remain dysfunctional after renal transplantation.

18 oncentration achievement of tacrolimus after renal transplantation.

19 ediated rejection is a major complication in renal transplantation.

20 ntal effect on early clinical outcomes after renal transplantation.

21 ts rejection with high sensitivity after non-renal transplantation.

22 ificant prognostic implications in pediatric renal transplantation.

23 tudy was to determine barriers to preemptive renal transplantation.

24 atomy can present a significant challenge to renal transplantation.

25 on, remain a major source of morbidity after renal transplantation.

26 n changes in the left ventricular mass after renal transplantation.

27 contributor to delayed graft function after renal transplantation.

28 on led to compelling success for outcomes of renal transplantation.

29 n changes in the left ventricular mass after renal transplantation.

30 ost common urological complication following renal transplantation.

31 o cases of AMR resistant to eculizumab after renal transplantation.

32 splantation and is especially feasible after renal transplantation.

33 year and after a follow-up of 3 years after renal transplantation.

34 P-2 deficiency in an isogenic mouse model of renal transplantation.

35 f anemia on patient and graft survival after renal transplantation.

36 and highly sensitized recipients undergoing renal transplantation.

37 educe IRI and improve organ preservation for renal transplantation.

38 f an intermediate period of EVNP in clinical renal transplantation.

39 on dialysis but improves significantly after renal transplantation.

40 are essential immunosuppressive drugs after renal transplantation.

41 tezomib to reduce anti-HLA antibodies before renal transplantation.

42 associated with donor-specific tolerance for renal transplantation.

43 ients who were desensitized for incompatible renal transplantation.

44 monitoring and detection of thrombosis after renal transplantation.

45 raft function (DGF) and graft survival after renal transplantation.

46 H in children with CKD on dialysis and after renal transplantation.

47 n pediatric patients undergoing living-donor renal transplantation.

48 sk stratifying patients being considered for renal transplantation.

49 outcomes following HLA antibody incompatible renal transplantation.

50 low-grade proteinuria or microalbuminuria in renal transplantation.

51 We report two cases of PLS occurring after renal transplantation.

52 true in both native kidney disease and after renal transplantation.

53 over the followup period, with 10 undergoing renal transplantation.

54 s (EVR) has demonstrated good efficacy after renal transplantation.

55 ctor for successful treatment outcomes after renal transplantation.

56 be exploited to improve clinical outcomes in renal transplantation.

57 tric patients during the first 2 years after renal transplantation.

58 trial of tolerance in HLA-identical sibling renal transplantation.

59 lation blocking agent CTLA4Ig, 7 days before renal transplantation.

60 patients who underwent primary living-donor renal transplantation.

61 graft thrombosis and early graft loss after renal transplantation.

62 ed by the immunosuppressive regimens used in renal transplantation.

63 ient has reached their final height or until renal transplantation.

64 lysis patients should not deter referral for renal transplantation.

65 erolimus-based treatment regimens in de novo renal transplantation.

66 motes graft function in an isograft model of renal transplantation.

67 -specific 3D printing into complex pediatric renal transplantation.

68 ce or prevent CNI-induced hypertension after renal transplantation.

69 s in living-related HLA-identical (LR HLAid) renal transplantation.

70 normalities that could be reversed following renal transplantation.

71 predictors of graft and patient survival in renal transplantation.

72 nt for 3 children who underwent living-donor renal transplantation.

73 planning in complex, living-donor pediatric renal transplantation.

74 s DGF and is a valid option to be applied in renal transplantation.

75 main higher with chronic dialysis than after renal transplantation.

76 ple aortic aneurysms, respectively underwent renal transplantation.

77 BKPyV-associated urothelial carcinoma after renal transplantation.

78 d risk of rejection in the early phase after renal transplantation.

79 arkers, with a specific focus on progress in renal transplantation.

80 s cancer have increasingly been accepted for renal transplantation.

81 termined as the need for chronic dialysis or renal transplantation.

82 he concept in clinical settings of islet and renal transplantation.

83 or exposure during the first 6 months after renal transplantation.

84 rfusion injury in a mouse model of congeneic renal transplantation.

85 el thrombosis is a severe complication after renal transplantation.

86 ich could eventually lead to applications in renal transplantation.

87 leting agent, is well tolerated in pediatric renal transplantation.

88 omorbidity still had a survival benefit from renal transplantation.

89 cause of renal graft loss after living-donor renal transplantation.

90 sion should be done with caution in LR HLAid renal transplantations.

91 e to support an absolute upper age limit for renal transplantation?

92 During the first year after renal transplantation, 14 patients developed severe infe

93 rom the ALERT trial (Assessment of Lescol in Renal Transplantation), a study comparing fluvastatin wi

94 2012 in the Assessment of Acute Rejection in Renal Transplantation (AART) study.

95 impacts racial disparities in deceased donor renal transplantation access has not been examined in th

96 In renal transplantation, acute rejection (AR) increases th

97 We identified 480 consecutive cases of renal transplantation after hand-assisted laparoscopic l

98 ney allocation variance to allow for delayed renal transplantation after liver transplantation may pr

99 llected follow-up data of published cases of renal transplantations after hematopoietic stem cell tra

100 Among 480 renal transplantations after living donor nephrectomy, u

101 ne samples from 221 individuals 1 year after renal transplantation (age 52 +/- 13 years, 55% male, 93

102 expanded mesenchymal stromal cells tested in renal transplantation, AKI, and CKD.

103 asses are at an increased risk for DGF after renal transplantation, although differences in non-death

104 objective was to determine BIPA's impact on renal transplantation among elderly patients (age >/=65

105 The utility of renal transplantation among individuals with two prior r

106 diovascular), with 655 patients censored for renal transplantation and 1183 for loss to follow-up.

107 tients undergoing antibody-incompatible (Ai) renal transplantation and 319 antibody-compatible transp

108 Dyslipidemia is a common finding after renal transplantation and a significant risk factor in t

109 -seropositive, recipient-seropositive (D+R+) renal transplantation and examined recipients' CMV antig

110 lyzed our institution's experience with HCV+ renal transplantation and factors contributing to subseq

111 luid from DCD (donation after cardiac death) renal transplantation and four isolates in the recipient

112 virus-6 (HHV-6) is known to reactivate after renal transplantation and has been associated with sever

113 hether antibodies to vimentin are made after renal transplantation and if production is associated wi

114 gh expression of WISE mRNA in a rat model of renal transplantation and in kidneys from normal rats.

115 Active HHV-6 infection occurs early after renal transplantation and is mostly asymptomatic.

116 chemia-reperfusion injury, pigs subjected to renal transplantation and liver transplantation patients

117 ed urinary protein excretion is common after renal transplantation and portends worse outcome.

118 scribe the frequency of return to work after renal transplantation and related characteristics.

119 l was used to analyze the chance of having a renal transplantation and the effect of transplantation

120 ous ureteroplasty of ureteric stenosis after renal transplantation and to compare the outcomes to tho

121 ial cause of humoral alloimmune responses in renal transplantation, and de novo donor-specific anti-h

122 mprovement of long-term graft survival after renal transplantation, and have potentially unlimited ap

123 oprine, a drug to prevent acute rejection in renal transplantation, and kaempferol and esculetin, two

124 toxicity from clinical studies of islet and renal transplantation, and of rapamycin as an anticancer

125 sion injury (IRI) remains a major problem in renal transplantation, and the inflammatory response to

126 clinically indicated as a CNI alternative in renal transplantation, and we have endeavored to develop

127 role of renin-angiotensin system blockade in renal transplantation are inconclusive.

128 graft outcomes in patients undergoing repeat renal transplantation are inferior compared to first-tim

129 nogenesis of urothelial carcinoma (UC) after renal transplantation are lacking.

130 sparities in clinical outcomes after de novo renal transplantation are well documented; whether the e

131 reatinine] x 1000, mg/mM) 1 year after first renal transplantation as predictors of transplant failur

132 etaphysis was performed within 2 weeks after renal transplantation (baseline) and 6 months later in 4

133 o determine the clinical relevance of T50 in renal transplantation, baseline serum T50 was measured i

134 Data of 1023 women, who underwent a renal transplantation between 1968 and 2008, were collec

135 tel Children's Hospital, UCLA, who underwent renal transplantation between January 2003 and October 2

136 an incident cohort of patients who underwent renal transplantation between June 2004 and September 20

137 lence and sequelae of EBV infection in adult renal transplantation beyond the first year.

138 To lessen barriers and facilitate renal transplantation, black men and women, white women,

139 on increases the risk of complications after renal transplantation, but the mechanisms controlling do

140 genesis of specific disease conditions after renal transplantation, but their utility as a biomarker

141 cells (MSCs) have protolerogenic effects in renal transplantation, but they induce long-term regulat

142 Delayed graft function (DGF) after renal transplantation can be diagnosed according to seve

143 (c) A renal transplantation can be performed in the absence of

144 Renal transplantation can be performed safely in childre

145 esistive index is routinely measured in many renal-transplantation centers for assessment of renal-al

146 n safety and efficacy of early (week 7 after renal transplantation) conversion from cyclosporine A (C

147 onic hepatitis C virus prohibiting cadaveric renal transplantation (CRT).

148 derwent bilateral nephrectomy and orthotopic renal transplantation (day 0).

149 This first series of EVNP in renal transplantation demonstrates that this technique i

150 Outcome after renal transplantation depends on patient compliance and

151 In the clinical settings of islet and renal transplantation, donor exosomes with respective ti

152 ort the feasibility and long-term results of renal transplantation during adulthood in patients with

153 In the setting of renal transplantation, eculizumab has so far proved effe

154 Racial disparities in access to renal transplantation exist, but the effects of race and

155 Renal transplantation experiments confirmed that extrare

156 To measure the risk of cancer in renal transplantation for recipients who had previously

157 etrospective review of patients assessed for renal transplantation from 2000 to 2009.

158 e 90 CMV-negative patients receiving a first renal transplantation from a CMV-positive donor in this

159 xperienced allograft dysfunction following a renal transplantation from a donation after cardiac deat

160 A retrospective review of the outcome of renal transplantation from pediatric donor (<18 years) k

161 t-beating donors were allowed to perform 236 renal transplantations from September 2005 to December 2

162 s function with caliper-matched living-donor renal transplantations from the Austrian dialysis and tr

163 Renal transplantation (from the same BMT donor) was perf

164 Renal transplantation has become the preferred treatment

165 Alloimmune risk stratification in renal transplantation has lacked the necessary prognosti

166 Urinary dd-cfDNA after renal transplantation has patient specific thresholds, r

167 target of rapamycin (mTOR) in the setting of renal transplantation has previously been associated wit

168 ugh simultaneous hematopoietic stem cell and renal transplantation has shown promising results, but i

169 Renal transplantation has transformed the life of patien

170 Short-term outcomes in renal transplantation have improved significantly in the

171 socioeconomic status (SES) on early steps of renal transplantation have not been well explored.

172 ely derived from the early Banff meetings on renal transplantation, have somewhat arbitrarily been ap

173 ctomy can be safely performed at the time of renal transplantation, however, carries a significantly

174 e rejection risk during the first year after renal transplantation.Impaired glucose tolerance was not

175 vated parathyroid hormone (PTH) level, after renal transplantation in a contemporary cohort.

176 -107 may help to better identify TCMVR after renal transplantation in a precise and clinically applic

177 potential benefit in patients with IGT after renal transplantation in addition to lifestyle modificat

178 Data on the outcome of renal transplantation in antineutrophil cytoplasmic anti

179 We performed renal transplantation in mice to model CAD and identifie

180 The benefit of renal transplantation in obese patients is controversial

181 ibed as a marker to predict thrombosis after renal transplantation in patients with antiphospholipid

182 erly have benefited from increased access to renal transplantation in recent years.

183 scusses current developments and outcomes of renal transplantation in systemic amyloidosis.

184 ribed after clinical ABO-incompatible (ABOi) renal transplantation in the 1980s and is recognized as

185 A total of 103 (24%) patients needed a renal transplantation in the LIST group with 16 (4%) rec

186 However, the feasibility of renal transplantation in the setting of cardiac dysfunct

187 The waiting time for deceased donor renal transplantation in the United States continues to

188 Racial disparities persist in access to renal transplantation in the United States, but the degr

189 iated with the development of diabetes after renal transplantation included older recipient age, fema

190 onor-specific antibody-secreting cells after renal transplantation indicates that B cells respond spe

191 jection may exist as early as 3 months after renal transplantation indicates that optimal management

192 emtuzumab as induction immunosuppression for renal transplantation introduces the possibility of long

193 Renal transplantation is a lifesaving intervention for e

194 icosteroid withdrawal/avoidance in pediatric renal transplantation is associated with a significant i

195 Renal transplantation is associated with reduction in th

196 alence of left ventricular hypertrophy after renal transplantation is blunted by high sodium intake.

197 ion in the prognosis of patients who undergo renal transplantation is controversial.

198 suppressive regimen in benefit-risk ratio in renal transplantation is debated.

199 It indicates that surveillance of LTBI after renal transplantation is important.

200 al premalignancies over a period of 40 years renal transplantation is presented.

201 Renal transplantation is the optimum treatment for end-s

202 Renal transplantation is the preferred treatment for pat

203 Renal transplantation is the renal replacement modality

204 matching and patient risk stratification in renal transplantation is the single antigen bead (SAB) a

205 of human leukocyte antigen (HLA) matching in renal transplantation is well recognized, with HLA-DR co

206 eperfusion injury (IRI), an obligate part of renal transplantation, is not yet well understood.

207 % of patients in end-stage renal disease and renal transplantation, is the main independent risk fact

208 Early after renal transplantation, it is often challenging to achiev

209 etric testing of the Knowledge Assessment of Renal Transplantation (KART).

210 eresis-based strategies with some success in renal transplantation, kidney paired donation (KPD) is a

211 We present our experience of living-donor renal transplantation (LDRT) using pretransplant stem ce

212 nce induction and sustenance in living donor renal transplantation (LDRT).

213 ciated with severe acute rejection following renal transplantation, leading us to investigate whether

214 Renal transplantation loss occurred in one patient who d

215 articularly lymphoceles, are not uncommon in renal transplantation, lymphangiectasia is a distinct co

216 We used a syngeneic rat renal transplantation model of IRI with bilaterally neph

217 In a murine CMV (MCMV) renal transplantation model, ganciclovir prophylaxis imp

218 This study, using a rhesus monkey renal transplantation model, sought to determine the app

219 lated in the glomeruli and arteries in a rat renal transplantation model.

220 Renal transplantation must increasingly serve a populati

221 Most focused on renal transplantation (n = 18, 53%) and used cross-secti

222 nts after heart transplantation (HTx, n=57), renal transplantation (n=1), or hematopoietic stem cell

223 ia is a feature of CKD and a complication of renal transplantation, often caused by impaired producti

224 or parathyroidectomy to define the impact of renal transplantation on circulating sclerostin levels a

225 dysfunction and in particular the effects of renal transplantation on markers of endothelial function

226 aim of our study was to assess the impact of renal transplantation on the survival of patients older

227 ing of cardiac dysfunction and the effect of renal transplantation on this progression remain poorly

228 The influence of DSA-SPA on repeat renal transplantation outcomes has not been previously s

229 The demand for renal transplantation outweighs the availability of orga

230 increased incidence of new-onset diabetes in renal transplantation patients over those receiving rapa

231 of the French national database for LR HLAid renal transplantations performed between 2002 and 2012.

232 In aggregate, the limited data on renal transplantation point to a high risk of disease re

233 n and calibration in the Patient Outcomes in Renal Transplantation (PORT) study cohort.

234 In vivo, after orthotopic RENCA cell renal transplantation, pulmonary tumor spread was inhibi

235 India with a population of 1.2 billion has a renal transplantation rate of 3.25 per million populatio

236 vestigated the determinants of depression in renal transplantation recipients (RTRs) and the associat

237 Prophylactic ureteric stenting in renal transplantation reduces major urological complicat

238 The principle barrier to renal transplantation referral before dialysis was patie

239 Infection after renal transplantation remains a major cause of morbidity

240 Renal transplantation remains contentious in patients wi

241 Renal transplantation remains the best treatment option

242 or the treatment of rheumatoid arthritis and renal transplantation, respectively.

243 muM] for healthy controls; P<0.001); whereas renal transplantation resulted in substantial reductions

244 During the last 20 years, waiting lists for renal transplantation (RT) have grown significantly olde

245 The impact of renal transplantation (RT) in the elderly with many como

246 he association of anemia with outcomes after renal transplantation (RT) is unclear.

247 iogenic factors on endothelial repair during renal transplantation (RT)-related ischemia-reperfusion.

248 is disease in immunosuppressed children with renal transplantation (RT).

249 dicts lower patient and graft survival after renal transplantation (RT).

250 S during in vivo cold storage and subsequent renal transplantation (RTx) and in vitro cold hypoxic re

251 , and fertility in adult male patients after renal transplantation (RTx) during childhood or adolesce

252 mothers after liver transplantation (LTx) or renal transplantation (RTx) with the assessment of certa

253 cohort comprising all children referred for renal transplantation (RTx) workup between 2009 and 2017

254 c antibodies (DSA) and poorer outcomes after renal transplantation (RTx).

255 of CMV-related complications in the de novo renal transplantation setting.

256 to reduce the high rate of AKI in the human renal transplantation setting.

257 We propose that the diagnosis of CRS after renal transplantation should be based on the following t

258 s after SLKT, our data strongly suggest that renal transplantation should be deferred in liver recipi

259 mpact significantly on CIT in deceased donor renal transplantation, some of which are modifiable; att

260 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a double-blind randomize

261 The Heme Oxygenase-1 in renal Transplantation study was a randomized, placebo-co

262 e placebo arm of the Assessment of Lescol in Renal Transplantation study, a randomized controlled tri

263 s a substudy of the Certican Nordic Trial in Renal Transplantation study, a randomized controlled tri

264 placebo group of the Assessment of Lescol in Renal Transplantation study.

265 rom this trial of tolerance in HLA-identical renal transplantation suggest that predictive genomic bi

266 urgeon versus urologist; history of previous renal transplantations; technique of ureteral anastomosi

267 times higher in patients on dialysis or post-renal transplantation than in the general population.

268 will return to insulin therapy after repeat renal transplantation, the relatively high frequency of

269 In renal transplantation, the use of immunoglobulin (Ig) cy

270 patient quality of care including access to renal transplantation therapy (RTT).

271 After renal transplantation, there is very high risk of diseas

272 donors has allowed expansion of living donor renal transplantation to account for one third of all re

273 We devised a model of renal transplantation to elucidate the initial stages of

274 and monitoring before and periodically after renal transplantation to prevent morbidity and mortality

275 Using the Assessment of Lescol in Renal Transplantation trial population, a formula for 7-

276 e used data from the Assessment of Lescol in Renal Transplantation trial, which are randomly divided

277 RTR derived from the Assessment of LEscol in Renal Transplantation trial.

278 ibe the case of a 52-year-old man awaiting a renal transplantation, undergoing elective orthopedic su

279 been some reports of acceptable outcomes of renal transplantation using kidneys from donors with DIC

280 en and 34.1% of the women were placed on the renal transplantation waiting list.

281 of pediatric patients on the deceased-donor renal transplantation waiting list.

282 Gender inequity in access to renal transplantation waiting lists, in favor of men, ha

283 significant mutation in INF2 In this family, renal transplantation was associated with post-transplan

284 Tacrolimus variability 6 to 12 months after renal transplantation was calculated, and outcomes were

285 Renal transplantation was the treatment of choice and ha

286 outbreak of A. baumannii emerging after DCD renal transplantation was tracked to understand the tran

287 s and mycophenolate mofetil (MMF) therapy in renal transplantation, we analyzed the peripheral B- and

288 tacept in patients with recurrent FSGS after renal transplantation, we investigated B7-1 expression i

289 layed graft function (DGF) in deceased donor renal transplantation, we undertook the efficacy of miro

290 s) from six UK hospitals who were undergoing renal transplantation were recruited and randomly assign

291 ion, the risks for four cancer groups during renal transplantation were significantly increased: anog

292 bruary 2010 and January 2012, a total of 217 renal transplantations were performed from living donors

293 A total of 27 218 renal transplantations were performed, of whom 163 had a

294 ty in preventing post-ischemic injury during renal transplantation, where acute kidney injury is know

295 increases the risks of four cancer types in renal transplantation while sparing the others.

296 sorders (PTLD) are a common malignancy after renal transplantation with a high incidence of PTLD desc

297 vels appear to show a biphasic pattern after renal transplantation with a rapid and profound decrease

298 Renal transplantation with alemtuzumab induction followe

299 on of transcriptional genomic information to renal transplantation, with specific reference to acute

300 In the brown Norway to Lewis rat renal transplantation, xenon administered to donor or re